Therasse P, Arback SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer (EORTC), Nat Cancer Inst of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

Kulke MH, Siu LL, Tepper JE et al (2011) Future directions in the treatment of neuroendocrine tumors; consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol 29:934–943CrossRefPubMedCentralPubMed

Sun W, Lipsitz S, Catalano P et al (2005) Phase II/III study of doxorubicin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 23:4897–4904CrossRefPubMed

Ekeblad S, Skogseid B, Öberg K et al (2008) Pancreatic endocrine tumors: survival and prognostic factors. Clin Cancer Res 14:7798–7803CrossRefPubMed

Murray-Lyon IM, Eddleston AL, Williams R et al (1968) Treatment of multiple-hormone-producing malignant islet-cell tumor with streptozotocin. Lancet 2:895–898CrossRefPubMed

Weiss R (1982) Streptozocin: a review of its pharmacology, efficacy and toxicity. Cancer 66:427–438

Moertel CG, Lavin PT, Hahn RG et al (1982) Phase II trial of doxorubicin for advanced islet cell carcinoma. Cancer 61:1567–1569

Ramanathan RK, Cnaan RG, Hahn G et al (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of Eastern Cooperative Oncology Group – E6282. Ann Oncol 12:1139–1143CrossRefPubMed

Middleton MR, Grob JJ, Aaronsson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 18:158–166PubMed

Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Ekeblad S, Sundin A, Janson ET et al (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986–2991CrossRefPubMed

Maire F, Hammel P, Faiver S et al (2009) Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology 90:67–72CrossRefPubMed

Crona J, Fanola J, Lindholm D et al (2013) Effect of temozolomide in metastatic bronchial carcinoids. Neuroendocrinology 98:151–155CrossRefPubMed

Ansell SM, Pitot HC, Burch PA et al (2001) A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91:1543–1548PubMed

Krzyzanowska MK, Tsao MS, Oza AM et al (2006) Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumors. Clin Oncol 18:88–89CrossRef

Kulke MH, Kim H, Clark JW et al (2004) A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101:934–939CrossRefPubMed

Ansell SM, Mahoney MR, Green EM et al (2004) Topotecan in patients with advanced neuroendocrine tumors; a phase II study with significant haematological toxicity. Am J Clin Oncol 27:232–235CrossRefPubMed

Moertel CG, Hanley JA, Johnson LA et al (1980) Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1195CrossRefPubMed

Moertel CG, Lefkopoulu M, Lipiz S et al (1992) Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523CrossRefPubMed